Carnosine Versus Placebo Treatment Study in Gulf War Illness (GWI) View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2008-2012

ABSTRACT

The purpose of this study is to perform a randomized double-blind, placebo-controlled, 12 week study of the effects of carnosine on cognitive, psychometric, autonomic, and muscle strength outcomes in 100 GWI subjects. Detailed Description Background: Homocarnosine (beta-alanine - gamma-aminobutyric acid) is one of the most abundant dipeptides in the brain. It has important antioxidant properties. Both beta-alanine and GABA are neurotransmitters, suggesting that cleavage of this dipeptide by carnosine dipeptidase 1 (CNDP1) may have important regulatory functions in vivo. Drug: Homocarnosine is not available. Carnosine (beta-alanine - histidine) is an over-the-counter dietary supplement that shares the antioxidant properties. We proposed that oral carnosine would be absorbed from the gut, cross the blood brain barrier, reduce presumed brain oxidant stress that participated in illness pathology, and improve subject health. Hypothesis: Carnosine supplementation for 12 weeks by mouth in Gulf War Illness subjects would improve cognitive and other outcomes compared to placebo treatment. Subjects: Gulf War Illness subjects met 1996 Fukuda criteria for Chronic Multisymptom Illness. Design: Pilot study. Double blind randomized placebo controlled with comparisons between Week 0 (Baseline, pre-randomization) and Week 12 (end of study) Outcomes: This pilot study included included cognitive testing, magnetic resonance imaging during the 2-back working memory task, self-report of psychometric and other subjective symptoms, tenderness testing by dolormetry, and pain threshold to assess reproducibility in the placebo-treated subjects, and potential treatment effects in the active study drug subjects. The study and each of the outcomes at weeks 0 and 12 are described in detail in the final published paper and in its extensive supplementary on-line materials (Baraniuk JN et al. Glob J Health Sci. 2013 5:69-81. PMID:23618477 PMCID:PMC4209301). An improvement on accuracy on the 2-back working memory task between 0 and 12 weeks was the primary outcome. Other evaluations were secondary outcomes. More... »

URL

https://clinicaltrials.gov/show/NCT00810368

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to perform a randomized double-blind, placebo-controlled, 12 week study of the effects of carnosine on cognitive, psychometric, autonomic, and muscle strength outcomes in 100 GWI subjects.\n\nDetailed Description\nBackground: Homocarnosine (beta-alanine - gamma-aminobutyric acid) is one of the most abundant dipeptides in the brain. It has important antioxidant properties. Both beta-alanine and GABA are neurotransmitters, suggesting that cleavage of this dipeptide by carnosine dipeptidase 1 (CNDP1) may have important regulatory functions in vivo. Drug: Homocarnosine is not available. Carnosine (beta-alanine - histidine) is an over-the-counter dietary supplement that shares the antioxidant properties. We proposed that oral carnosine would be absorbed from the gut, cross the blood brain barrier, reduce presumed brain oxidant stress that participated in illness pathology, and improve subject health. Hypothesis: Carnosine supplementation for 12 weeks by mouth in Gulf War Illness subjects would improve cognitive and other outcomes compared to placebo treatment. Subjects: Gulf War Illness subjects met 1996 Fukuda criteria for Chronic Multisymptom Illness. Design: Pilot study. Double blind randomized placebo controlled with comparisons between Week 0 (Baseline, pre-randomization) and Week 12 (end of study) Outcomes: This pilot study included included cognitive testing, magnetic resonance imaging during the 2-back working memory task, self-report of psychometric and other subjective symptoms, tenderness testing by dolormetry, and pain threshold to assess reproducibility in the placebo-treated subjects, and potential treatment effects in the active study drug subjects. The study and each of the outcomes at weeks 0 and 12 are described in detail in the final published paper and in its extensive supplementary on-line materials (Baraniuk JN et al. Glob J Health Sci. 2013 5:69-81. PMID:23618477 PMCID:PMC4209301). An improvement on accuracy on the 2-back working memory task between 0 and 12 weeks was the primary outcome. Other evaluations were secondary outcomes.", 
    "endDate": "2012-07-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00810368", 
    "keywords": [
      "Gulf War Illness", 
      "carnosine", 
      "muscle strength", 
      "beta-alanine", 
      "gamma-Aminobutyric Acid", 
      "dipeptides", 
      "brain", 
      "antioxidant property", 
      "Neurotransmitter Agent", 
      "cleavage", 
      "important regulatory function", 
      "vivo", 
      "drug", 
      "histidine", 
      "dietary supplement", 
      "gut", 
      "blood-brain barrier", 
      "oxidant stress", 
      "pathology", 
      "health", 
      "supplementation", 
      "mouth", 
      "placebo treatment", 
      "criterion", 
      "chronic multisymptom illness", 
      "Pilot Project", 
      "Double-Blind", 
      "comparison", 
      "baseline", 
      "cognitive testing", 
      "Magnetic Resonance Imaging", 
      "memory task", 
      "self-report", 
      "subjective symptom", 
      "tenderness", 
      "pain threshold", 
      "reproducibility", 
      "treated subject", 
      "potential treatment", 
      "active study", 
      "detail", 
      "published paper", 
      "on-line material", 
      "improvement", 
      "accuracy", 
      "primary outcome", 
      "Evaluation Study as Topic", 
      "Secondary outcome"
    ], 
    "name": "Carnosine Versus Placebo Treatment Study in Gulf War Illness (GWI)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00810368"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00006.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.213910.8", 
        "type": "Organization"
      }
    ], 
    "startDate": "2008-08-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1471-2377-5-22", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000085714", 
          "https://doi.org/10.1186/1471-2377-5-22"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/aje/155.11.1033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000710746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.54.8.2320", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011308665"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/08830738020170111501", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063854061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5539/gjhs.v5n3p69", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072947490"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00810368"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00810368'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00810368'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00810368'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00810368'


 

This table displays all metadata directly associated to this object as RDF triples.

83 TRIPLES      16 PREDICATES      68 URIs      57 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00810368 schema:about anzsrc-for:3053
2 schema:description The purpose of this study is to perform a randomized double-blind, placebo-controlled, 12 week study of the effects of carnosine on cognitive, psychometric, autonomic, and muscle strength outcomes in 100 GWI subjects. Detailed Description Background: Homocarnosine (beta-alanine - gamma-aminobutyric acid) is one of the most abundant dipeptides in the brain. It has important antioxidant properties. Both beta-alanine and GABA are neurotransmitters, suggesting that cleavage of this dipeptide by carnosine dipeptidase 1 (CNDP1) may have important regulatory functions in vivo. Drug: Homocarnosine is not available. Carnosine (beta-alanine - histidine) is an over-the-counter dietary supplement that shares the antioxidant properties. We proposed that oral carnosine would be absorbed from the gut, cross the blood brain barrier, reduce presumed brain oxidant stress that participated in illness pathology, and improve subject health. Hypothesis: Carnosine supplementation for 12 weeks by mouth in Gulf War Illness subjects would improve cognitive and other outcomes compared to placebo treatment. Subjects: Gulf War Illness subjects met 1996 Fukuda criteria for Chronic Multisymptom Illness. Design: Pilot study. Double blind randomized placebo controlled with comparisons between Week 0 (Baseline, pre-randomization) and Week 12 (end of study) Outcomes: This pilot study included included cognitive testing, magnetic resonance imaging during the 2-back working memory task, self-report of psychometric and other subjective symptoms, tenderness testing by dolormetry, and pain threshold to assess reproducibility in the placebo-treated subjects, and potential treatment effects in the active study drug subjects. The study and each of the outcomes at weeks 0 and 12 are described in detail in the final published paper and in its extensive supplementary on-line materials (Baraniuk JN et al. Glob J Health Sci. 2013 5:69-81. PMID:23618477 PMCID:PMC4209301). An improvement on accuracy on the 2-back working memory task between 0 and 12 weeks was the primary outcome. Other evaluations were secondary outcomes.
3 schema:endDate 2012-07-01T00:00:00Z
4 schema:keywords Double-Blind
5 Evaluation Study as Topic
6 Gulf War Illness
7 Magnetic Resonance Imaging
8 Neurotransmitter Agent
9 Pilot Project
10 Secondary outcome
11 accuracy
12 active study
13 antioxidant property
14 baseline
15 beta-alanine
16 blood-brain barrier
17 brain
18 carnosine
19 chronic multisymptom illness
20 cleavage
21 cognitive testing
22 comparison
23 criterion
24 detail
25 dietary supplement
26 dipeptides
27 drug
28 gamma-Aminobutyric Acid
29 gut
30 health
31 histidine
32 important regulatory function
33 improvement
34 memory task
35 mouth
36 muscle strength
37 on-line material
38 oxidant stress
39 pain threshold
40 pathology
41 placebo treatment
42 potential treatment
43 primary outcome
44 published paper
45 reproducibility
46 self-report
47 subjective symptom
48 supplementation
49 tenderness
50 treated subject
51 vivo
52 schema:name Carnosine Versus Placebo Treatment Study in Gulf War Illness (GWI)
53 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00810368
54 schema:sdDatePublished 2019-03-07T15:23
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N861854aa7f664906a8d18cfc7833a8f6
57 schema:sponsor https://www.grid.ac/institutes/grid.213910.8
58 schema:startDate 2008-08-01T00:00:00Z
59 schema:subjectOf sg:pub.10.1186/1471-2377-5-22
60 https://doi.org/10.1093/aje/155.11.1033
61 https://doi.org/10.1177/08830738020170111501
62 https://doi.org/10.2337/diabetes.54.8.2320
63 https://doi.org/10.5539/gjhs.v5n3p69
64 schema:url https://clinicaltrials.gov/show/NCT00810368
65 sgo:license sg:explorer/license/
66 sgo:sdDataset clinical_trials
67 rdf:type schema:MedicalStudy
68 N861854aa7f664906a8d18cfc7833a8f6 schema:name Springer Nature - SN SciGraph project
69 rdf:type schema:Organization
70 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
71 rdf:type schema:DefinedTerm
72 sg:pub.10.1186/1471-2377-5-22 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000085714
73 https://doi.org/10.1186/1471-2377-5-22
74 rdf:type schema:CreativeWork
75 https://doi.org/10.1093/aje/155.11.1033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000710746
76 rdf:type schema:CreativeWork
77 https://doi.org/10.1177/08830738020170111501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063854061
78 rdf:type schema:CreativeWork
79 https://doi.org/10.2337/diabetes.54.8.2320 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011308665
80 rdf:type schema:CreativeWork
81 https://doi.org/10.5539/gjhs.v5n3p69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072947490
82 rdf:type schema:CreativeWork
83 https://www.grid.ac/institutes/grid.213910.8 schema:Organization
 




Preview window. Press ESC to close (or click here)


...